Table 3.
Overall survival according to cytogenetic abnormalities or to the World Health Organization (WHO) classification of myeloid neoplasias.
| Variable/Subtypes | n | Probability of overall survival at 5 years (S.E.) | p |
|---|---|---|---|
| Cytogenetic abnormalitiesa | |||
| Patients with a normal karyotype | 17 | 56.6% (±12.7%) | |
| Patients with t(15;17) | 21 | 81.0% (±8.6%) | |
| Patients with t(8;21) | 7 | 71.4% (±17.1%) | 0.028 |
| Patients with myelodysplasia-related changes | 13 | 20.5% (±12.0%) | |
| Patients with other abnormalities | 16 | 46.9% (±13.4%) | |
| WHO classification | |||
| Patients with recurrent genetic abnormalities | 45 | 71.0% (±5.8%) | |
| Patients with myelodysplasia-related changes | 16 | 28.1% (±12.2%) | 0.011 |
| Patients with AML not otherwise specified | 19 | 36.1% (±11.2%) | |
| Patients with AML associated with Down syndrome | 6 | 83.3% (±15.2%) | |
a
Three recurrent genetic abnormalities [inv(16) or t(16;16), t(9;11), and t(1;22)] were excluded from this analysis because only two patients in each subtype were detected (see Table 2).